All patients underwent standard medical therapy post-PCI, incorporating antiplatelet agents, statins, and ACEI/ARB/ARNI, beta-blockers to reduce ischemic events and improve outcomes
5,12,13 These efforts have yielded six GLP-1 RAsstarting with the development of exendin-4 (Figure 1B)-based exenatide (Figure 1C), followed by liraglutide (Figure 1D), albiglutide, dulaglutide (Figure 1E), lixisenatide, and semaglutide (Figure 1F)that have been approved by the United States Food and Drug Administration (US FDA) to treat type 2 diabetes
Monitoring focuses on broad health markers, with copper-specific labs reserved for repeated or higher systemic exposure contexts
41 YamotoMFukumotoKTakahashiTMiyakeHNakayaKNomuraAet al
Wegovy , on the other hand, is specifically approved for long-term weight management
Increased potency and stability means less IGF-1 LR3 is needed compared to unmodified IGF-1.